Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BPL003
MIFTS: 56

Bipolar Disorder

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Bipolar Disorder

About this section

MalaCards integrated aliases for Bipolar Disorder:

Name: Bipolar Disorder 12 74 52 25 36 54 42 43 15 17 71
Major Affective Disorder 52 39 71
Bipolar Affective Disorder 52 25
Depression, Bipolar 25 71
Bipolar Depression 12 15
Manic Depression 12 52
Manic Disorder 12 71
Manic Bipolar Affective Disorder 12
Bipolar Disorder Manic Phase 12
Bipolar Affective Psychosis 25
Major Affective Disorder 1 71
Manic-Depressive Psychosis 52
Major Affective Disorder 2 71
Manic Depressive Disorder 12
Bipolar Spectrum Disorder 25
Manic Bipolar I Disorder 12
Manic Depressive Illness 25
Affective Disorder Major 54
Depressive-Manic Psych. 12
Bipolar Disorder, Mixed 71
Mixed Bipolar Disorder 12
Depression Bipolar 54
Bipolar Illness 52

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases
Anatomical: Mental diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:3312
KEGG 36 H01653
MeSH 43 D001714
ICD10 32 F31
UMLS 71 C0005586 C0005587 C0024713 more
Sources

Summaries for Bipolar Disorder

About this section
KEGG : 36 Bipolar disorder, previously known as manic depressive illness, is a severe chronic mood disorder, characterized by the recurrence of mania (hypomania), depression, or mixed episodes. It is one of the main causes of disability among young people, leading to cognitive and functional impairment and raised mortality, particularly death by suicide. Mania is the most characteristic phase of bipolar disorder. While mood elevation and euphoria are commonly described phenotypic descriptors of mania, irritability and anger may dominate. At the present time, there is solid evidence supporting the use of lithium, the anticonvulsants valproate and carbamazepine, and some antipsychotics in mania. Manic or hypomanic episodes differ in severity and length. In a hypomanic episode, a disturbance in functioning can be seen by others but does not typically cause severe impairment or require admission to hospital. At onset, most patients with bipolar disorder present with a depressive episode that differs subtly from unipolar depression. The first step in the management of bipolar disorder is to confirm the diagnosis of mania or hypomania and define the patient's mood state, because the therapeutic approach differs considerably for hypomania, mania, depression, and euthymia. While effective pharmacological treatments exist for bipolar disorder, the pathophysiology of the condition essentially remains unknown. Although bipolar disorder is one of the most heritable psychiatric disorders, a multifactorial model in which gene and environment interact is currently thought to best fit this disorder. Many risk alleles of small effect which are described in genome-wide association studies, contribute to the polygenic risk of bipolar disorder. It is suggested that the dopaminergic system may play a central role in bipolar disorder, although no singular dysfunction of neurotransmitter systems has been identified.

MalaCards based summary : Bipolar Disorder, also known as major affective disorder, is related to mood disorder and schizoaffective disorder. An important gene associated with Bipolar Disorder is DISC2 (Disrupted In Schizophrenia 2), and among its related pathways/superpathways are Neurotransmitter Clearance In The Synaptic Cleft and Methylphenidate Pathway, Pharmacodynamics. The drugs Eleuthero and Coal tar have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes.

Disease Ontology : 12 A mood disorder that involves alternating periods of mania and depression.

Genetics Home Reference : 25 Bipolar disorder is a mental health condition that causes extreme shifts in mood, energy, and behavior. This disorder most often appears in late adolescence or early adulthood, although symptoms can begin at any time of life. People with bipolar disorder experience both dramatic "highs," called manic episodes, and "lows," called depressive episodes. These episodes can last from hours to weeks, and many people have no symptoms between episodes. Manic episodes are characterized by increased energy and activity, irritability, restlessness, an inability to sleep, and reckless behavior. Depressive episodes are marked by low energy and activity, a feeling of hopelessness, and an inability to perform everyday tasks. People with bipolar disorder often have repeated thoughts of death and suicide, and they have a much greater risk of dying by suicide than the general population. Manic and depressive episodes can include psychotic symptoms, such as false perceptions (hallucinations) or strongly held false beliefs (delusions). Mixed episodes, which have features of manic and depressive episodes at the same time, also occur in some affected individuals. Bipolar disorder often occurs with other mental health conditions, including anxiety disorders (such as panic attacks), behavioral disorders (such as attention-deficit/hyperactivity disorder), and substance abuse.

NIH Rare Diseases : 52 Bipolar disorder is a type of mental illness that causes unusual shifts in mood, energy, activity levels, sleep and behavior. Signs and symptoms typically include alternating periods of manic episodes (joyful or excited states) and depressive episodes (very sad, hopeless or empty states). Mood episodes may also include symptoms of both mania and depression (a mixed state). It often develops in the late teens or early adult years, but age of onset can range from childhood to late in life. Bipolar disorder can run in families, although no single gene is thought to cause the condition. Many factors acting together likely increase a person's risk to develop the disorder. Treatment may include medication and psychotherapy for preventing relapses and reducing the severity of symptoms.

MedlinePlus : 42 Bipolar disorder is a serious mental illness. People who have it go through unusual mood changes. They go from very happy, "up," and active to very sad and hopeless, "down," and inactive, and then back again. They often have normal moods in between. The up feeling is called mania. The down feeling is depression. The causes of bipolar disorder aren't always clear. It runs in families. Abnormal brain structure and function may also play a role. Bipolar disorder often starts in a person's late teen or early adult years. But children and adults can have bipolar disorder too. The illness usually lasts a lifetime. If you think you may have it, tell your health care provider. A medical checkup can rule out other illnesses that might cause your mood changes. If not treated, bipolar disorder can lead to damaged relationships, poor job or school performance, and even suicide. However, there are effective treatments to control symptoms: medicine and talk therapy. A combination usually works best. NIH: National Institute of Mental Health

Wikipedia : 74 Bipolar disorder, previously known as manic depression, is a mental disorder characterized by periods of... more...

Sources

Related Diseases for Bipolar Disorder

About this section

Diseases in the Bipolar Disorder family:

Bipolar Ll Disorder Bipolar I Disorder

Diseases related to Bipolar Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 720)
# Related Disease Score Top Affiliating Genes
1 mood disorder 34.4 SLC6A4 RELN PRODH IMPA1 DRD3 DISC2
2 schizoaffective disorder 34.3 SLC6A4 RELN PRODH DRD3 DISC2 DISC1
3 major depressive disorder 34.3 SLC6A4 DRD3 DISC2 DISC1 COMT BDNF
4 schizophrenia 34.3 SLC6A4 RELN PRODH DRD3 DISC2 DISC1
5 psychotic disorder 34.2 SLC6A4 RELN PRODH DRD3 DISC1 DAOA
6 bipolar i disorder 34.1 SLC6A4 DRD3 COMT BDNF
7 depression 34.0 SLC6A4 RELN DISC2 BDNF
8 cyclothymic disorder 33.7 DISC1 DAOA COMT
9 migraine with or without aura 1 33.6 SLC6A4 DRD3 COMT BDNF
10 asperger syndrome 33.6 SLC6A4 DISC1 COMT BDNF
11 schizophrenia 9 33.3 PRODH DISC1
12 mental depression 33.3 SLC6A4 PRODH DRD3 DISC1 COMT BDNF
13 substance abuse 32.9 SLC6A4 PRODH DRD3 COMT BDNF
14 anxiety 32.9 SLC6A4 PRODH DRD3 COMT BDNF
15 attention deficit-hyperactivity disorder 32.9 SLC6A4 PRODH DRD3 COMT BDNF
16 schizophrenia 2 32.8 PRODH DISC2 DISC1
17 personality disorder 32.8 SLC6A4 DRD3 COMT BDNF
18 endogenous depression 32.7 SLC6A4 COMT BDNF
19 alcohol use disorder 32.6 SLC6A4 DRD3 COMT BDNF
20 panic disorder 32.5 SLC6A4 DRD3 DAOA-AS1 DAOA COMT BDNF
21 obsessive-compulsive disorder 32.5 SLC6A4 DRD3 COMT BDNF
22 borderline personality disorder 32.5 SLC6A4 COMT BDNF
23 autism 32.4 SLC6A4 RELN PRODH DRD3 DISC1 COMT
24 eating disorder 32.4 SLC6A4 DRD3 COMT BDNF
25 alcohol dependence 32.3 SLC6A4 DRD3 COMT BDNF
26 generalized anxiety disorder 32.2 SLC6A4 PRODH COMT BDNF
27 autism spectrum disorder 32.2 SLC6A4 RELN PRODH DRD3 DISC2 DISC1
28 disease of mental health 32.1 SLC6A4 RELN PRODH DRD3 DISC1 COMT
29 substance dependence 32.1 SLC6A4 DRD3 COMT BDNF
30 social phobia 32.1 SLC6A4 PRODH COMT BDNF
31 post-traumatic stress disorder 32.0 SLC6A4 COMT BDNF
32 tobacco addiction 32.0 SLC6A4 DRD3 COMT BDNF
33 pervasive developmental disorder 32.0 SLC6A4 RELN PRODH DRD3 DISC1 COMT
34 oppositional defiant disorder 31.9 SLC6A4 DISC2 COMT
35 tardive dyskinesia 31.9 DRD3 COMT
36 postpartum depression 31.8 SLC6A4 COMT BDNF
37 acute stress disorder 31.8 SLC6A4 BDNF
38 agoraphobia 31.8 SLC6A4 COMT BDNF
39 schizophreniform disorder 31.7 PRODH DRD3 DISC1 COMT BDNF
40 dysthymic disorder 31.7 SLC6A4 PRODH DISC2 BDNF
41 paranoid schizophrenia 31.7 SLC6A4 DISC1 COMT BDNF
42 cocaine dependence 31.7 SLC6A4 DRD3 COMT
43 fibromyalgia 31.6 SLC6A4 COMT BDNF
44 phobia, specific 31.6 SLC6A4 PRODH COMT
45 bulimia nervosa 31.6 SLC6A4 COMT BDNF
46 gilles de la tourette syndrome 31.6 SLC6A4 DRD3 COMT BDNF
47 drug dependence 31.6 SLC6A4 DRD3 BDNF
48 tic disorder 31.6 SLC6A4 PRODH DRD3 COMT
49 traumatic brain injury 31.6 COMT BDNF
50 irritable bowel syndrome 31.5 SLC6A4 COMT BDNF

Comorbidity relations with Bipolar Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Diabetes Insipidus, Nephrogenic, Autosomal
Hypertension, Essential Hypothyroidism
Major Affective Disorder 9 Major Depressive Disorder
Parkinson Disease, Late-Onset Schizophrenia
Schizophreniform Disorder Tardive Dyskinesia

Graphical network of the top 20 diseases related to Bipolar Disorder:



Diseases related to Bipolar Disorder
Sources

Symptoms & Phenotypes for Bipolar Disorder

About this section
Sources

Drugs & Therapeutics for Bipolar Disorder

About this section

Drugs for Bipolar Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 430)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Eleuthero Approved, Experimental Phase 4
2
Coal tar Approved Phase 4 8007-45-2
3
Reboxetine Approved, Experimental Phase 4 98769-81-4, 71620-89-8 123628 65856
4
Topiramate Approved Phase 4 97240-79-4 5284627
5
Levetiracetam Approved Phase 4 102767-28-2 441341
6
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 497540 5095
7
Cycloserine Approved Phase 4 68-41-7 401 6234
8
Sertraline Approved Phase 4 79617-96-2 68617
9
Norepinephrine Approved Phase 4 51-41-2 439260
10
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
11
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
12
Memantine Approved, Investigational Phase 4 19982-08-2 4054
13
Asenapine Approved Phase 4 65576-45-6, 85650-56-2 3001386
14
Histamine Approved, Investigational Phase 4 51-45-6 774
15
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
16
Iloperidone Approved Phase 4 133454-47-4 71360
17
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
18
Oxcarbazepine Approved Phase 4 28721-07-5 34312
19
Brexpiprazole Approved, Investigational Phase 4 913611-97-9 11978813
20
Methohexital Approved Phase 4 151-83-7 9034
21
Donepezil Approved Phase 4 120014-06-4 3152
22
Galantamine Approved Phase 4 357-70-0 9651
23
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
24
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
25
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
26
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
27
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
28
Nortriptyline Approved Phase 4 72-69-5 4543
29
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
30
Dipyridamole Approved Phase 4 58-32-2 3108
31
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
32
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
33
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
34
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
35
Metformin Approved Phase 4 657-24-9 14219 4091
36
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
37
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
38
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
39
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
40
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
41
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
42
Acetaminophen Approved Phase 4 103-90-2 1983
43
Lorazepam Approved Phase 4 846-49-1 3958
44
Loxapine Approved Phase 4 1977-10-2 3964
45
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
46
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
47
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
48
Simvastatin Approved Phase 4 79902-63-9 54454
49
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
50
Racepinephrine Approved Phase 4 329-65-7 838

Interventional clinical trials:

(show top 50) (show all 1597)
# Name Status NCT ID Phase Drugs
1 Assessing the Efficacy of Left Repetitive Transcranial Magnetic Stimulation (rTMS) as an Adjunctive Treatment to Mood Stabilizers for the Treatment of Bipolar Depression Unknown status NCT01583023 Phase 4 Bupropion
2 Algorithm Guided Treatment Strategies for Bipolar Depression Unknown status NCT01938859 Phase 4 Lithium;Quetiapine;Shuganjieyu capsule
3 Effects of N-Acetyl-Cysteine on Oxidative Stress Biomarkers in Bipolar Patients With and Without Tobacco Use Disorder Unknown status NCT02252341 Phase 4
4 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression. Unknown status NCT00335205 Phase 4 ropinirole
5 Exploring Alterations of Central Autonomic Modulation in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
6 Clinical Psychopharmacology Division Institute of Mental Health, Peking University Unknown status NCT03148535 Phase 4 Lithium Carbonate;lithium carbonate combined with SSRI antidepressant treatment
7 An Open Label, Multicenter, Single Arm, 4-Week Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
8 An Exploratory Randomized Open Comparison of Oxtellar XR® vs Oxcarbazepine IR (Trileptal®) for the Treatment of Bipolar Depression Unknown status NCT03567681 Phase 4 Extended release oxcarbazepine vs Immediate release oxcarbazepine
9 Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder Unknown status NCT00608075 Phase 4 lithium;Lithium
10 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
11 Assessment and Follow Up Study of Children and Adolescent With Bipolar Disorder Unknown status NCT01000402 Phase 4 Psychopharmacotherapy
12 A Randomized Open-label Active-controlled Study to Evaluate the Efficacy and Safety of Utapine Versus Seroquel in Patients With Bipolar Mania Unknown status NCT01043679 Phase 4 Utapine;Seroquel
13 Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
14 Open Label Prophylaxis Study of Lithium Plus Extended- Release Carbamazepine (Equetro®) Combination for Rapid Cycling Bipolar Disorder Unknown status NCT00325286 Phase 4 Lithium Plus Extended- Release Carbamazepine
15 Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs Unknown status NCT01182012 Phase 4
16 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
17 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients. Unknown status NCT01246310 Phase 4
18 Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness Unknown status NCT02845440 Phase 4
19 Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia Unknown status NCT00838032 Phase 4 Quetiapine fumarate;Haloperidol
20 Phase 3 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study Unknown status NCT00426946 Phase 4 Reboxetine
21 D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression Unknown status NCT02772211 Phase 4 Ketamine;D-cycloserine;Placebo
22 Maintenance Therapies in Bipolar Disorder Completed NCT00227968 Phase 4
23 A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression Completed NCT00363337 Phase 4 aripiprazole
24 Olanzapine/Fluoxetine Combination Versus Lamotrigine in the Treatment of Bipolar I Depression Completed NCT00485771 Phase 4 Olanzapine;Fluoxetine;Lamotrigine
25 A Randomized, Sham Controlled, Crossover Trial of rTMS for Bipolar Depression Completed NCT00186758 Phase 4
26 Bipolar Depression Assessment Study on Tx Response Completed NCT00191399 Phase 4 Olanzapine;Fluoxetine
27 Phase 4 Study: Double-blind Placebo-controlled Trial of Depakote-ER for Depressive and Anxiety Symptoms in Non-refractory Bipolar Depression Completed NCT00226343 Phase 4 Depakote-ER
28 A Randomized, Double-blind, Placebo-controlled Study of the Efficacy of Ropinirole in the Treatment of Depression in Bipolar Disorder Completed NCT00314821 Phase 4 ropinirole
29 12- Week Open Label Treatment of Refractory Bipolar Depression (BD) With Combination of Depakote ER (DEP) and Aripiprazole (AZP) Completed NCT00223496 Phase 4 Aripiprazole
30 A Phase IV STudy of the Effectiveness of Quetiapine Extended Release 600mg Once a Day to Control the Symptoms of Manic Phase of Bipolar Disorder. Completed NCT00521365 Phase 4 Quetiapine 600mg
31 A Double-Blind, Placebo-Controlled Trial of Lamotrigine In Individuals With Bipolar Disorder and Comorbid Alcohol Dependence Completed NCT01015586 Phase 4 Lamotrigine;Placebo
32 A Randomized, Open-label, Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide Completed NCT01416220 Phase 4 Lithium;Paroxetine
33 Prevention of Relapse & Recurrence of Bipolar Depression Completed NCT00961961 Phase 4 Lithium / Fluoxetine;Lithium / Placebo
34 An Investigation of Sleep Architecture in Ziprasidone-Treated Bipolar Depression Completed NCT00835107 Phase 4 ziprasidone hydrochloride;placebo
35 Depakote ER in Bipolar Depression Completed NCT00186186 Phase 4 Depakote ER
36 Double-Blind, Acute Depression Study Comparing Venlafaxine XR and Lamotrigine When Added to Mood Stabilizer in the Treatment of Bipolar Depression Completed NCT00188643 Phase 4 Venlafaxine and Lamotrigine
37 NMDA Antagonists in Bipolar Depression Completed NCT01833897 Phase 4 Standard of Care;Ketamine;D-cycloserine
38 A Pilot Open Study of the Safety and Effectiveness of Lamotrigine for the Treatment of Mania in Youth Ages 6-17 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorders Completed NCT00181844 Phase 4 lamotrigine
39 Open-Label Study of Quetiapine for Mania In Preschool Children 4 to 6 Years of Age With Bipolar and Bipolar Spectrum Disorder Completed NCT00181883 Phase 4 quetiapine
40 Aripiprazole in Late Life Bipolar Disorder Completed NCT00194038 Phase 4 Aripiprazole
41 Lamictal As Add on Treatment in Mixed States of Bipolar Disorder Completed NCT00223509 Phase 4 Lamotrigine
42 Open-Label Pilot Study of Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder Completed NCT00181779 Phase 4 aripiprazole (Abilify)
43 An Investigation of the Sleep Architecture and Consequent Cognitive Changes in Olanzapine-Treated Depressed Patients Completed NCT00520507 Phase 4 Olanzapine;Placebo
44 Orally-Disintegrating vs. Regular Olanzapine Tablets: Effects on Weight and GI Hormones Completed NCT00384332 Phase 4 orally-disintegrating olanzapine;regular olanzapine
45 Open-Label Study of Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder Completed NCT00181870 Phase 4 carbamazepine ER (Equetro)
46 Tranylcypromine Treatment of Bipolar Depression Completed NCT01430455 Phase 4 Tranylcypromine
47 18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder Completed NCT03902613 Phase 4 Lurasidone
48 Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium in Bipolar Disorder: Identification of Cellular and Molecular Targets Clinically Relevant Completed NCT01919892 Phase 4 Lithium
49 Minocycline for Bipolar Disorder Completed NCT01514422 Phase 4 Minocycline
50 Open-Label Study of Concerta in the Treatment of ADHD in Youth and Adults With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder Completed NCT00181987 Phase 4 methylphenidate HCl (Concerta)

Search NIH Clinical Center for Bipolar Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carbamazepine
Clonazepam
Clozapine
CLOZAPINE (CARACO)
CLOZAPINE (CLOZARIL)
CLOZAPINE (IVAX)
CLOZAPINE (TEVA)
CLOZAPINE (VERSACLOZ)
Divalproex Sodium
Fazaclo
gabapentin
gabapentin enacarbil
lamotrigine
Lithium
Lithium Aspartate
Lithium Carbonate
lithium citrate
Mylan brand of clozapine
olanzapine
quetiapine
Quetiapine fumarate
Risperidone
Sodium Valproate
tiagabine
Tiagabine hydrochloride
topiramate
UDL brand of clozapine
Valproic Acid

Cochrane evidence based reviews: bipolar disorder

Sources

Genetic Tests for Bipolar Disorder

About this section
Sources

Anatomical Context for Bipolar Disorder

About this section

MalaCards organs/tissues related to Bipolar Disorder:

40
Brain, Cortex, Testes, Prefrontal Cortex, Amygdala, Eye, Thyroid
Sources

Publications for Bipolar Disorder

About this section

Articles related to Bipolar Disorder:

(show top 50) (show all 26246)
# Title Authors PMID Year
1
Toxoplasmosis in a Cohort of Italian Patients With Bipolar and Psychotic Disorders: How Infection May Affect Clinical Features? 61 42
31985560 2020
2
Enhancing adherence to antipsychotic treatment for bipolar disorders. Comparison of mobile app-based psychoeducation, group psychoeducation, and the combination of both: protocol of a three-arm single-blinded parallel-group multi-centre randomised trial. 42
32141476 2020
3
Suicide - Rewriting My Story. 42
32212517 2020
4
Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes. 61 54
20060128 2010
5
Analysis of a polymorphic microRNA target site in the purinergic receptor P2RX7 gene. 61 54
20446288 2010
6
Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression. 61 54
20067857 2010
7
Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. 54 61
20080186 2010
8
Differential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder. 61 54
20072116 2010
9
Association of polymorphisms of the tryptophan hydroxylase 2 gene with risk for bipolar disorder or suicidal behavior. 61 54
19800079 2010
10
DISC1 duplication in two brothers with autism and mild mental retardation. 61 54
20002455 2010
11
Allele specific analysis of the ADRBK2 gene in lymphoblastoid cells from bipolar disorder patients. 54 61
19766236 2010
12
Association analyses between brain-expressed fatty-acid binding protein (FABP) genes and schizophrenia and bipolar disorder. 54 61
19554614 2010
13
Association between Serotonin-Related Polymorphisms in 5HT2A, TPH1, TPH2 Genes and Bipolar Disorder in Korean Population. 54 61
20396435 2010
14
Influence of neuregulin1 genotype on neural substrate of perceptual matching in children. 61 54
19967439 2010
15
Translin-associated factor X gene (TSNAX) may be associated with female major depressive disorder in the Japanese population. 54 61
19760522 2010
16
Higher striatal dopamine transporters in euthymic patients with bipolar disorder: a SPECT study with [Tc] TRODAT-1. 54 61
20148872 2010
17
N-methyl-D-aspartate receptor expression in parvalbumin-containing inhibitory neurons in the prefrontal cortex in bipolar disorder. 61 54
20148871 2010
18
Mutation screening and assessment of the effect of genetic variations on expression and RNA editing of serotonin receptor 2C in the human brain. 61 54
20015120 2010
19
Positive association between the brain-derived neurotrophic factor (BDNF) gene and bipolar disorder in the Han Chinese population. 61 54
19330778 2010
20
NK1 (TACR1) receptor gene 'knockout' mouse phenotype predicts genetic association with ADHD. 61 54
19204064 2010
21
Association study of PDE4B gene variants in Scandinavian schizophrenia and bipolar disorder multicenter case-control samples. 61 54
19350560 2010
22
NRG1 gene in recurrent major depression: no association in a large-scale case-control association study. 54 61
19367584 2010
23
Catechol-O-methyltransferase Val158Met polymorphism affects therapeutic response to mood stabilizer in symptomatic manic patients. 61 54
20004480 2010
24
Met carriers of BDNF Val66Met genotype show increased N-acetylaspartate concentration in the anterior cingulate cortex. 61 54
19683059 2010
25
State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: a meta-analytic study. 61 54
19786073 2009
26
Genetics of attention-deficit hyperactivity disorder (ADHD). 54 61
19715710 2009
27
Genetic variation in neuregulin1 is associated with differences in prefrontal engagement in children. 61 54
19449332 2009
28
Levels of neuregulin 1 and 3 proteins in Brodmann's area 46 from subjects with schizophrenia and bipolar disorder. 61 54
19765633 2009
29
The effect of COMT, BDNF, 5-HTT, NRG1 and DTNBP1 genes on hippocampal and lateral ventricular volume in psychosis. 54 61
19573260 2009
30
Association between the serotonin 2A receptor gene and bipolar affective disorder in an Australian cohort. 61 54
19584773 2009
31
Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis. 54 61
19501841 2009
32
Common and rare variants of DAOA in bipolar disorder. 61 54
19194963 2009
33
Association studies and gene expression analyses of the DISC1-interacting molecules, pericentrin 2 (PCNT2) and DISC1-binding zinc finger protein (DBZ), with schizophrenia and with bipolar disorder. 54 61
19191256 2009
34
Glucocorticoid receptor polymorphisms in major depression. Focus on glucocorticoid sensitivity and neurocognitive functioning. 61 54
19906241 2009
35
The Val/Met functional polymorphism in COMT confers susceptibility to bipolar disorder: evidence from an association study and a meta-analysis. 54 61
19578924 2009
36
Genetic variation in the G72 (DAOA) gene affects temporal lobe and amygdala structure in subjects affected by bipolar disorder. 54 61
19689504 2009
37
Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder. 61 54
19689509 2009
38
Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. 61 54
19473667 2009
39
Association of the dystrobrevin binding protein 1 gene (DTNBP1) in a bipolar case-control study (BACCS). 54 61
19089808 2009
40
DISC1 association, heterogeneity and interplay in schizophrenia and bipolar disorder. 54 61
18317464 2009
41
No association between lithium full responders and the DRD1, DRD2, DRD3, DAT1, 5-HTTLPR and HTR2A genes in a Sardinian sample. 54 61
19647327 2009
42
Phosphorylation status of glucocorticoid receptor, heat shock protein 70, cytochrome c and Bax in lymphocytes of euthymic, depressed and manic bipolar patients. 61 54
19359101 2009
43
The use of triiodothyronine as an augmentation agent in treatment-resistant bipolar II and bipolar disorder NOS. 61 54
19215985 2009
44
Preliminary evidence on the association between XBP1-116C/G polymorphism and response to prophylactic treatment with valproate in bipolar disorders. 54 61
19564049 2009
45
Positron emission tomography quantification of serotonin-1A receptor binding in medication-free bipolar depression. 61 54
19278673 2009
46
Changes in gyrification over 4 years in bipolar disorder and their association with the brain-derived neurotrophic factor valine(66) methionine variant. 61 54
19167700 2009
47
Family-based association study of Neuregulin 1 with psychotic bipolar disorder. 61 54
19127563 2009
48
BDNF is not associated with schizophrenia: data from a Japanese population study and meta-analysis. 61 54
19406621 2009
49
Evidence for the association of the DAOA (G72) gene with schizophrenia and bipolar disorder but not for the association of the DAO gene with schizophrenia. 61 54
19586533 2009
50
Serotonin receptor 2C and mental disorders: genetic, expression and RNA editing studies. 61 54
19411841 2009